Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States.
Flawless balance sheet with limited growth.
Share Price & News
How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PI6's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PI6 underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: PI6 underperformed the German Market which returned -20.6% over the past year.
Price Volatility Vs. Market
How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Pieris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PI6's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PI6's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PI6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PI6 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PI6's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PI6 is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.4x).
How is Pieris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PI6 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PI6 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PI6 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PI6's revenue (22.9% per year) is forecast to grow faster than the German market (4% per year).
High Growth Revenue: PI6's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PI6's Return on Equity is forecast to be high in 3 years time
How has Pieris Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PI6 is currently unprofitable.
Growing Profit Margin: PI6 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PI6 is unprofitable, and losses have increased over the past 5 years at a rate of -17.4% per year.
Accelerating Growth: Unable to compare PI6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PI6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: PI6 has a negative Return on Equity (-49.6%), as it is currently unprofitable.
How is Pieris Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: PI6's short term assets ($115.0M) exceed its short term liabilities ($27.0M).
Long Term Liabilities: PI6's short term assets ($115.0M) exceed its long term liabilities ($62.7M).
Debt to Equity History and Analysis
Debt Level: PI6 is debt free.
Reducing Debt: PI6 has no debt compared to 5 years ago when its debt to equity ratio was 7%.
Inventory Level: PI6 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PI6's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PI6 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PI6 has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of -12.4% each year.
What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PI6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PI6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PI6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PI6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PI6's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Yoder (43yo)
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD2.62M) is above average for companies of similar size in the German market ($USD431.53K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||5.33yrs||US$2.62m||0.011% $11.6k|
|Principal Financial & Accounting Officer and Treasurer||0.58yr||no data||0.0092% $9.9k|
|Senior VP of Corporate Operations||no data||no data||no data|
|Senior VP & Chief Scientific Officer||0.67yr||no data||no data|
|Director of Investor Relations||no data||no data||no data|
|Vice President of Human Resources||2.25yrs||no data||no data|
|Head of Discovery & Alliance Management and VP||no data||no data||no data|
|Senior VP & Head of Translational Science||no data||no data||no data|
|Senior VP & Head of Business Development||no data||no data||no data|
|Senior VP & Head of Clinical Development||no data||no data||no data|
Experienced Management: PI6's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|CEO, President & Director||5.33yrs||US$2.62m||0.011% $11.6k|
|Independent Director||5.33yrs||US$144.40k||no data|
|Independent Director||3.58yrs||US$152.76k||0.018% $19.4k|
|Independent Director||1.58yrs||US$105.52k||no data|
|Independent Director||1.5yrs||US$99.96k||no data|
|Independent Director||2yrs||US$154.03k||no data|
|Independent Director||4.92yrs||US$139.95k||no data|
|Director||0.67yr||no data||no data|
Experienced Board: PI6's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pieris Pharmaceuticals, Inc.
- Ticker: PI6
- Exchange: DB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$115.394m
- Listing Market Cap: US$106.959m
- Shares outstanding: 55.21m
- Website: https://www.pieris.com
Number of Employees
- Pieris Pharmaceuticals, Inc.
- 255 State Street
- 9th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PIRS||NasdaqCM (Nasdaq Capital Market)||Yes||New Common Stock||US||USD||Dec 2014|
|PI6||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Dec 2014|
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 21:54|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.